Human medicines European public assessment report (EPAR): Fulvestrant Mylan, fulvestrant, Date of authorisation: 08/01/...
Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Faslodex, and do not need to be repeated for Fulvestrant Mylan. As for every medicine, the company provided studies on …